Quick Answer
HOOKIPA Pharma Inc. reported Operating Income Loss of -$51.46 million for the year ending 2024.
- HOOKIPA Pharma Inc. showed an increase of +47.3% in Operating Income Loss from 2023 to 2024.
- This data is from HOOKIPA Pharma Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$6.45 million | Q2 2018: -$6.98 million | Q3 2018: -$5.55 million | Q1 2019: -$10.66 million | Q2 2019: -$13.63 million | Q3 2019: -$13.58 million | Q1 2020: -$12.46 million | Q2 2020: -$9.23 million | Q3 2020: -$16.41 million | Q1 2021: -$19.17 million | Q2 2021: -$19.29 million | Q3 2021: -$21.17 million | Q1 2022: -$20.15 million | Q2 2022: -$18.43 million | Q3 2022: -$20.99 million | Q1 2023: -$22.66 million | Q2 2023: -$21.47 million | Q3 2023: -$22.67 million | Q1 2024: $11.11 million | Q2 2024: -$22.46 million | Q3 2024: -$18.64 million | Q1 2025: -$17.87 million.
- Over the full 8 years of available data (2017 to 2024), HOOKIPA Pharma Inc.'s Operating Income Loss has declined by 263.5%.
- Historical annual values: Fiscal year 2024: -$51.46 million | Fiscal year 2023: -$97.69 million | Fiscal year 2022: -$73.16 million | Fiscal year 2021: -$81.67 million | Fiscal year 2020: -$53.29 million | Fiscal year 2019: -$51.09 million | Fiscal year 2018: -$21.18 million | Fiscal year 2017: -$14.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: